1An empirical study on influencing factors of capital investment in cooperative innovation in China's pharmaceutical manufacturing industryFAN Ming-jie, QU Feng-hong1345-13492Reflections on real world research under the evidence system of"three combinations"registration and evaluation of new traditional Chinese medicineAN Na, HAN Ling, CHEN Ping-yan1359-13633Pharmaceutical considerations on the development of generic drugs of nebulizer suspensionYANG Wen-zhi, NING Li-li1364-13664Progress in research on cardiovascular protective mechanism of glucagon-like peptide-1 receptor agonistsCUI Xin, WEI Xiao-tong, YAN Wen-hui, CHEN Li-na1367-13715Research progress in oral delivery technology of therapeutic peptidesHUANG Kan, SUN Min-jie1380-13866Research and development strategy of vaccine for emergent infectious diseases: Taking the COVID-19 pneumonia as an exampleYAN Shu, YANG Xiao-yi, YANG Yu-sheng, CHEN Juan, LU Yan, OUYANG Zhao-lian1387-13947A benchmarking analysis for improvement of whole process management of investigator initiated trialsWU Rong, LU Ting-ting, HU Dan, ZHU Zhu1402-14068Preparation process optimization, characterization and dissolution characteristics of dihydromyricetin nanoparticlesLI Zi-rui, LU Hui-ling, XIAO Yi-fei, LI Ya1411-14199Synthesis of piperlongumine derivatives and their inhibitory effects on doxorubicin-resistant strain of human K562 leukemiaDING Ze-dan, TIAN Jian-hui, TAN Shu-dan, WANG Chuan, ZOU Yu1433-144010Network Meta analysis and pharmacoeconomic evaluation of three drugs in the treatment of acute ischemic strokeJING Jun-kai, SUN Li-hua1441-1448